Compositions for targeted delivery of siRNA
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
1. A composition for delivering an RNA interference polynucleotide to a liver cell in vivo comprising:
wherein,
P is a membrane active polyamine
L 2 is a disubstituted maleamate linkage,
M 1 is a charge neutral masking agent containing a galactose derivative having affinity for the asialoglycoprotein receptor,
M 2 is a charge neutral masking agent containing a polyethylene glycol (PEG),
y is an integer greater than 1
z is an integer greater than or equal to zero
the value y+z is greater than 50% of the number of amines on P,
N is an RNA interference polynucleotide,
A comprises a hydrophobic group having at least 20 carbon atoms, and
cleavage of L 2 restores amines and membrane activity of P.
2. The composition of claim 1 wherein the RNA interference polynucleotide is selected from the group consisting of: DNA, RNA, dsRNA, siRNA, and miRNA.
3. The composition of claim 1 wherein the liver cell consists of a hepatocyte.
4. The composition of claim 1 wherein the membrane active polyamine contains two or more different monomers.
5. The composition of claim 4 wherein the membrane active polyamine is composed of amine-containing monomers and lower hydrophobic group-containing monomers wherein said lower hydrophobic groups contain 1-6 carbon atoms.
6. The composition of claim 5 wherein said lower hydrophobic groups contain 2-6 carbon atoms.
7. The composition of claim 6 wherein the lower hydrophobic group consists of a butyl group.
8. The composition of claim 4 wherein the membrane active polyamine is composed of amine-containing monomers, and lower hydrophobic group-containing monomers, and higher hydrophobic group-containing monomers wherein said lower hydrophobic groups contain 1-6 carbon atoms and said lower hydrophobic groups contain 12-36 carbon atoms.
9. The composition of claim 8 wherein the lower hydrophobic group consists of a butyl group and the higher hydrophobic group consists of an octadecyl or dodecyl group.
10. The composition of claim 1 wherein the membrane active polyamine is soluble in water.
11. The composition of claim 1 wherein the reversibly masked membrane active polyamine
is soluble in water.
12. The composition of claim 1 wherein the membrane active polyamine is a random copolymer.
13. The composition of claim 12 wherein the random copolymer is selected from the group consisting of poly(vinyl ether) and poly(acrylate).
14. The composition of claim 8 wherein the amine-containing monomers, lower hydrophobic group-containing monomers, and higher hydrophobic group-containing monomers are present in a ratio of 4-8 amine-containing monomers: 3-5 lower hydrophobic group-containing monomers: 1 higher hydrophobic group-containing monomers.
15. The composition of claim 1 wherein the value y+z is greater than 70% of the number of amines on the membrane active polyamine.
16. The composition of claim 15 wherein the value y+z is greater than 80% of the number of amines on the membrane active polyamine.
17. The composition of claim 1 wherein the composition is provided in a pharmaceutically acceptable carrier or diluent.
18. The composition of claim 1 wherein N is linked to A via a physiologically labile linkage L 1 .
19. The composition of claim 18 wherein L 1 is a physiologically labile covalent linkage that is orthogonal to L 2 .
20. The composition of claim 1 wherein the ratio of galactose derivative to PEG linked to the membrane active polyamine is 1 to 0.5-2.
21. The composition of claim 1 wherein the galactose derivative consists of an N-acetylgalactosamine.
22. The composition of claim 1 wherein the hydrophobic group comprises cholesterol.
23. The composition of claim 1 wherein the hydrophobic group comprises a cholesterol derivative.
24. The composition of claim 1 wherein P-(L 2 -M 1 ) comprises the structure represented by:
25. A composition for delivering an oligonucleotide to a liver cell in vivo comprising:
a) an oligonucleotide covalently linked to a hydrophobic group having at least 20 carbon atoms; and,
b) a reversibly masked and targeted amphipathic polymer comprising a polymer synthesized from amine-containing monomers and lower hydrophobic group-containing monomers to which a plurality of galactose derivatives are linked to said polymer via pH labile disubstituted maleamate bonds and wherein cleavage of said pH labile disubstituted maleamate bonds yields amine groups thereby generating a membrane active polyamine.
26. The composition of claim 25 wherein a plurality of polyethylene glycol moieties are linked to said polymer via pH labile disubstituted maleamate bonds.
27. A method of manufacturing an RNA oligonucleotide delivery composition comprising:
a) forming a membrane active polyamine;
b) forming a first masking agent comprising a charge neutral disubstituted maleic anhydride containing a galactose derivative;
c) optionally forming a second masking agent comprising a charge neutral disubstituted maleic anhydride containing a polyethylene glycol;
d) reversibly inhibiting membrane activity of the membrane active polyamine wherein the inhibiting consists of modifying 50% or more of the amines on the polyamine by reacting the polyamine with a plurality of first masking agents and optionally at least one second masking agent thereby linking a plurality of galactose derivatives and optionally at least one polyethylene glycol to the membrane active polymer via physiologically pH-labile disubstituted maleamate linkages; and,
e) linking the RNA interference polynucleotide to a hydrophobic group having at least 20 carbon atoms;
f) providing the RNA interference polynucleotide and the reversibly inhibited membrane active polyamine in solution suitable for administration in vivo.